Market Research Logo

Conference Documentation: Immunogenicity

Conference Documentation: Immunogenicity

SMi is proud to announce the return of their 3rd annual Immunogenicity event to London in 2016! Biologics is a leading growth area in the Pharmaceutical industry with growth rates 2 -3 times as fast as chemical entities.* The challenges for the biopharmaceutical market are different to those from traditional chemical entities. Immunogenicity continues to be a major concern for the field of science, due to its impact on safety and efficacy. The challenging task of immunogenicity assessment of a biopharmaceutical drug’s immunogenic potential remains at the forefront of challenges.

Immunogenicity of an antigen is frequently encountered in the context of vaccine development, an area of intense interest currently due to the emergence or re-emergence of infectious pathogens with the potential for worldwide spread. With the global vaccine market expected to reach $84.44 billion by 2022, now is the time engage with industry experts to addresses the real challenges with immunogenicity including assay assessment, the role of aggregation, the introduction of nanobodies and many more!


Day 1
8:30
Registration & Coffee
9:00
Chairman's Opening Remarks
Annie Groot, CEO/CSO, EpiVax, Inc.
9:10
Improving the efficacy and safety profile of biotherapeutics by addressing product immunogenicity with tolerogenic nanoparticles
Takashi Kei Kishimoto , Chief Scientific Officer, Selecta Biosciences
9:50
How to switch off unwanted immune responses
Adnan Khan, Senior Scientist Immunology/Pharmacology, UCB
10:30
Morning Coffee
11:00
A harmonised approach to interpretation and reporting of clinical immunogenicity data
Daniel Sikkema, Head BioPharma Clinical Immunology, GSK
11:40
Towards harmonisation of immunogenicity assays
Meenu Wadhwa, Head, Cytokines & Growth Factors & Biotherapeutics, NIBSC, MHRA
12:20
Networking Lunch
13:50
Immunogenicity risk assessment tools for biologics
Jochem Gokemeijer, Associate Director, Bristol Myers Squibb
14:30
Integrating best-in-class in vitro and ex vivo assays to manage immunogenicity risk in biologics
Jeremy Fry, Director of Sales, ProImmune Ltd.
15:10
Afternoon Tea
15:40
Nanobodies, a promising new class of biopharmaceuticals: What about their immunogenicity?
Chloe Ackaert, Postdoctoral Researcher, Cellular and Molecular Immunology, Free University Of Brussels
16:20
Understanding the role of aggregation in the immunogenicity of biotherapeutic proteins
Jeremy Derrick, Professor, University Of Manchester
17:00
Chairman’s Closing Remarks and Close of Day One
Annie Groot, CEO/CSO, EpiVax, Inc.
Day 2
8:30
Registration & Coffee
9:00
Chairman's Opening Remarks
Adnan Khan, Senior Scientist Immunology/Pharmacology, UCB
9:10
Development and validation of cell based antibody neutralisation assays
Sue Charlton, Scientific Lead, Vaccine Research Group, , Public Health England
9:50
Integration of immunogenicity risk data to forecast clinical outcomes
Timothy Hickling, Immunogenicity Sciences Discipline Lead, Pfizer Pharmaceuticals
10:30
Morning Coffee
11:00
Influence of Aggregates on in vitro T Cell Responses
Mark Fogg, Immunology Group Leader, Abzena
11:40
T cell amplification assays for immunogenicity prediction: T cell repertoire and epitopes
Machteld Tiemessen, Senior Scientist, Janssen
12:20
Networking Lunch
13:50
Correlation of T-cell responses induced by therapeutic cancer vaccines with clinical responses
Kees Melief, Chief Scientific Officer, ISA Pharmaceuticals
14:30
A computational pipeline for personalized cancer vaccine development
Annie Groot, CEO/CSO, EpiVax, Inc.
15:10
Afternoon Tea
15:40
Immunogenicity of biosimilar monoclonal antibodies
Andreas Herrmann, CEO, Baliopharm AG
16:20
Synthetic vaccine particles (SVPs) for the prevention of anti-drug antibodies (ADAs)
Mantas Malisauskas, Manager R&D, Baxalta
17:00
Chairman’s Closing Remarks and Close of Day Two
Adnan Khan, Senior Scientist Immunology/Pharmacology, UCB

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report